IL136285A0 - Pharmaceutical compositions containing an acid-labile active component - Google Patents

Pharmaceutical compositions containing an acid-labile active component

Info

Publication number
IL136285A0
IL136285A0 IL13628598A IL13628598A IL136285A0 IL 136285 A0 IL136285 A0 IL 136285A0 IL 13628598 A IL13628598 A IL 13628598A IL 13628598 A IL13628598 A IL 13628598A IL 136285 A0 IL136285 A0 IL 136285A0
Authority
IL
Israel
Prior art keywords
acid
pharmaceutical compositions
active component
compositions containing
labile active
Prior art date
Application number
IL13628598A
Other languages
English (en)
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26042262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL136285(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997154324 external-priority patent/DE19754324A1/de
Priority claimed from DE1998122549 external-priority patent/DE19822549A1/de
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of IL136285A0 publication Critical patent/IL136285A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13628598A 1997-12-08 1998-12-08 Pharmaceutical compositions containing an acid-labile active component IL136285A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997154324 DE19754324A1 (de) 1997-12-08 1997-12-08 Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
DE1998122549 DE19822549A1 (de) 1998-05-20 1998-05-20 Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
PCT/EP1998/008036 WO1999029320A1 (fr) 1997-12-08 1998-12-08 Nouvelle forme galenique comprenant un compose actif acido-labile

Publications (1)

Publication Number Publication Date
IL136285A0 true IL136285A0 (en) 2001-05-20

Family

ID=26042262

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13628598A IL136285A0 (en) 1997-12-08 1998-12-08 Pharmaceutical compositions containing an acid-labile active component
IL13624998A IL136249A0 (en) 1997-12-08 1998-12-08 Suppository containing an acid-labile active compound
IL136249A IL136249A (en) 1997-12-08 2000-05-21 Suppository containing an

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL13624998A IL136249A0 (en) 1997-12-08 1998-12-08 Suppository containing an acid-labile active compound
IL136249A IL136249A (en) 1997-12-08 2000-05-21 Suppository containing an

Country Status (16)

Country Link
US (5) US6383510B1 (fr)
EP (4) EP1037607B1 (fr)
JP (2) JP4612184B2 (fr)
AT (3) ATE303809T1 (fr)
AU (2) AU751066B2 (fr)
CA (2) CA2310585C (fr)
DE (3) DE69842173D1 (fr)
DK (2) DK1037607T3 (fr)
EE (2) EE04800B1 (fr)
ES (4) ES2392684T3 (fr)
HU (2) HUP0100043A2 (fr)
IL (3) IL136285A0 (fr)
PL (2) PL195266B1 (fr)
PT (1) PT1037607E (fr)
SI (2) SI1037634T1 (fr)
WO (2) WO1999029320A1 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
ATE303809T1 (de) * 1997-12-08 2005-09-15 Altana Pharma Ag Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
ATE293981T1 (de) * 1998-09-21 2005-05-15 Amato Pharm Prod Ltd System zur oralen wirkstoffabgabe zur steigerung der bioverfügbarkeit von aktiviertem glycyrrhetin
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
PT1187601E (pt) 1999-06-07 2005-11-30 Altana Pharma Ag Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
KR100647901B1 (ko) * 1999-07-09 2006-11-17 보령제약 주식회사 세파클러-함유 서방성 약제조성물 및 그의 제조방법
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US7357943B2 (en) * 2000-12-07 2008-04-15 Nycomed Gmbh Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
EP1341524B1 (fr) * 2000-12-07 2011-10-19 Nycomed GmbH Preparation pharmaceutique en pate comprenant un ingredient actif labile en milieu acide
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
CN1876647A (zh) * 2001-02-02 2006-12-13 特瓦制药工业有限公司 苯并咪唑化合物产品
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2260837A1 (fr) * 2001-06-01 2010-12-15 Pozen, Inc. Compositions pharmaceutiques pour l'administration coordonnée d'AINS
GB0120123D0 (en) * 2001-08-17 2001-10-10 Upperton Ltd Preparation of microparticles
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
EP1572151A1 (fr) * 2002-07-03 2005-09-14 Abbott Laboratories Formes dosifiees liquides contenant un inhibiteur de pompe a protons
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
WO2004073654A2 (fr) * 2003-02-20 2004-09-02 Santarus, Inc. Liberation immediate d'un complexe antacide d'omeprazole presentant une nouvelle formulation pour une elimination rapide et prolongee d'acide gastrique
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
KR101179012B1 (ko) 2003-03-10 2012-09-03 니코메드 게엠베하 로플루미라스트 신규한 제조 방법
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
CA2529984C (fr) 2003-06-26 2012-09-25 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI337877B (en) * 2003-07-18 2011-03-01 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005032554A1 (fr) 2003-10-03 2005-04-14 Astron Research Pvt. Ltd Nouveau systeme d'administration transmucosale
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
PT1691787E (pt) * 2003-12-04 2008-09-02 Pfizer Prod Inc Método de formação de multipartículas farmacêuticas
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
WO2005053653A1 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Procede d'atomisation/congelation faisant appel a une extrudeuse pour la preparation de compositions d'azithromycine multiparticulaires contenant de preference un poloxamere et un glyceride
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053639A2 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
WO2005076987A2 (fr) * 2004-02-10 2005-08-25 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un tampon et d'un medicament anti-inflammatoire non steroidien
US20050214370A1 (en) * 2004-03-26 2005-09-29 Sarama Robert J Stable coating agent comprising sterol
CA2560595C (fr) * 2004-03-29 2013-01-22 Wyeth Complements nutritionnels mineraux multivitamines
US8968768B2 (en) 2004-03-29 2015-03-03 Wyeth Llc Phytosterol nutritional supplements
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060034934A1 (en) * 2004-08-13 2006-02-16 Deguise Matthew L Agglomeration of sterol particles
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN101107013A (zh) 2004-11-22 2008-01-16 阿纳迪斯有限公司 生物活性组合物
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
AU2006224619B2 (en) 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
EP1747776A1 (fr) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique comprenant du pantoprazole granulaire
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
RU2467747C2 (ru) 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
EP2338477A1 (fr) 2009-12-15 2011-06-29 bene-Arzneimittel GmbH Suppositoire comportant du pantoprazole
EP2611416B1 (fr) * 2010-09-03 2015-08-19 Pharmaterials Ltd. Composition pharmaceutique pour l'utilisation avec un inhalateur de poudre seche
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012171540A1 (fr) 2011-06-15 2012-12-20 Bene-Arzneimittel Gmbh Suppositoire comportant du pantoprazole contenu dans des pastilles avec un noyau de cellulose
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3544614A4 (fr) 2016-11-28 2020-08-05 Lipocine Inc. Traitement oral à base d'undécanoate de testostérone
CN117338729B (zh) * 2023-12-06 2024-02-13 山东国邦药业有限公司 一种硫氰酸红霉素可溶性颗粒及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931147A (en) * 1959-10-23 1963-07-10 Olin Mathieson Sustained release pharmaceutical preparations and methods for their manufacture
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
JPH05194224A (ja) * 1992-09-17 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
EP0642797B1 (fr) * 1993-09-09 2000-05-17 Takeda Chemical Industries, Ltd. Formulation comprenant un agent antibactérien et un agent antiulcère
JPH07145053A (ja) * 1993-11-25 1995-06-06 Yoshitomi Pharmaceut Ind Ltd 坐 剤
BR9506018A (pt) * 1994-07-08 1997-09-02 Astra Ab Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiferos e no homem e embalagem de ampola de pressão transversal
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
ATE303809T1 (de) * 1997-12-08 2005-09-15 Altana Pharma Ag Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz

Also Published As

Publication number Publication date
SI1037607T1 (en) 2004-08-31
US6569453B2 (en) 2003-05-27
ES2392684T3 (es) 2012-12-12
EP1371361A1 (fr) 2003-12-17
CA2312493A1 (fr) 1999-06-17
EP1525882A1 (fr) 2005-04-27
US6328993B1 (en) 2001-12-11
ATE500815T1 (de) 2011-03-15
CA2310585C (fr) 2005-08-23
IL136249A (en) 2007-07-04
JP4546643B2 (ja) 2010-09-15
EP1037634A1 (fr) 2000-09-27
WO1999029299A1 (fr) 1999-06-17
EE200000331A (et) 2001-08-15
EE200000329A (et) 2001-08-15
AU751066B2 (en) 2002-08-08
PL195266B1 (pl) 2007-08-31
ATE303809T1 (de) 2005-09-15
ATE260090T1 (de) 2004-03-15
CA2310585A1 (fr) 1999-06-17
DK1037607T3 (da) 2004-06-21
JP2001525366A (ja) 2001-12-11
DE69842173D1 (de) 2011-04-21
ES2216351T3 (es) 2004-10-16
US20020025342A1 (en) 2002-02-28
EP1525882B1 (fr) 2012-08-08
EP1037634B1 (fr) 2005-09-07
DE69821976T2 (de) 2004-12-16
US20020090397A1 (en) 2002-07-11
EE04576B1 (et) 2006-02-15
WO1999029320A1 (fr) 1999-06-17
ES2362418T3 (es) 2011-07-05
PL341055A1 (en) 2001-03-26
EE04800B1 (et) 2007-04-16
PL196163B1 (pl) 2007-12-31
JP4612184B2 (ja) 2011-01-12
IL136249A0 (en) 2001-05-20
US20040022854A1 (en) 2004-02-05
EP1371361B1 (fr) 2011-03-09
AU2413099A (en) 1999-06-28
AU2160099A (en) 1999-06-28
PT1037607E (pt) 2004-07-30
DE69831504T2 (de) 2006-06-14
AU748209B2 (en) 2002-05-30
US6383510B1 (en) 2002-05-07
DE69831504D1 (de) 2005-10-13
DE69821976D1 (de) 2004-04-01
SI1037634T1 (sl) 2006-02-28
CA2312493C (fr) 2007-03-06
US6884437B2 (en) 2005-04-26
HUP0100043A2 (hu) 2001-08-28
EP1037607B1 (fr) 2004-02-25
US6607742B2 (en) 2003-08-19
PL341054A1 (en) 2001-03-26
DK1037634T3 (da) 2005-12-19
ES2249849T3 (es) 2006-04-01
HUP0100065A2 (hu) 2001-08-28
JP2001525355A (ja) 2001-12-11
EP1037607A1 (fr) 2000-09-27

Similar Documents

Publication Publication Date Title
IL136285A0 (en) Pharmaceutical compositions containing an acid-labile active component
UA32525C2 (uk) Стійка до шлункового соку форма лікарського засобу на основі пантопразолу для орального введення
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
HUP9801692A3 (en) Benzimidazole compounds, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions
HRP980163B1 (en) Pharmaceutical composition for the oral administration of an n-piperidinopyrazole -3-carboxamide derivative, its salts and their solvates
HK1029060A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
IL116673A (en) Stable oral pharmaceutical composition containing an acid labile benzimidazole
ZA965866B (en) 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
GEP20032995B (en) 1-Amino-Alkylcyclohexane NMDA Receptor Antagonists
ZA962536B (en) Pharmaceutical composition for transdermal administration.
GR3032366T3 (en) Pharmaceutical cyclosporin composition.
PL334100A1 (en) Cyclosporin containing compositions for oral administration
HU9802795D0 (en) Pharmaceutical compositions containing more active components
IT1287174B1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
ZA961138B (en) Solid active ingredient compositions containing hydroxypropylcellulose.
AU5812800A (en) Pharmaceutical preparation
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
IL114673A (en) Pharmaceutical compositions containing protein for oral administration
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
CS240991A3 (en) Solid forms for oral administration, said forms containing iphosphamide as active component
UA32598C2 (uk) Спосіб одержання лікарської форми карбамазепіну
IL131703A0 (en) Pharmaceutical compositions in the form of soft gelatine capsule containing cyclosporin
HUP0101012A3 (en) Pharmaceutical composition for oral administration
HU9701051D0 (en) Pharmaceutical compositions containing natural active components

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees